183 related articles for article (PubMed ID: 8104329)
1. p53 oncogene mutations in three human prostate cancer cell lines.
Carroll AG; Voeller HJ; Sugars L; Gelmann EP
Prostate; 1993; 23(2):123-34. PubMed ID: 8104329
[TBL] [Abstract][Full Text] [Related]
2. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53.
Nesslinger NJ; Shi XB; deVere White RW
Cancer Res; 2003 May; 63(9):2228-33. PubMed ID: 12727844
[TBL] [Abstract][Full Text] [Related]
3. Chromosome 17p deletions and p53 mutations in renal cell carcinoma.
Reiter RE; Anglard P; Liu S; Gnarra JR; Linehan WM
Cancer Res; 1993 Jul; 53(13):3092-7. PubMed ID: 8319216
[TBL] [Abstract][Full Text] [Related]
4. p53 oncogene mutations in human prostate cancer specimens.
Voeller HJ; Sugars LY; Pretlow T; Gelmann EP
J Urol; 1994 Feb; 151(2):492-5. PubMed ID: 7904314
[TBL] [Abstract][Full Text] [Related]
5. An uncertain role for p53 gene alterations in human prostate cancers.
Brooks JD; Bova GS; Ewing CM; Piantadosi S; Carter BS; Robinson JC; Epstein JI; Isaacs WB
Cancer Res; 1996 Aug; 56(16):3814-22. PubMed ID: 8706029
[TBL] [Abstract][Full Text] [Related]
6. P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer.
Massenkeil G; Oberhuber H; Hailemariam S; Sulser T; Diener PA; Bannwart F; Schäfer R; Schwarte-Waldhoff I
Anticancer Res; 1994; 14(6B):2785-90. PubMed ID: 7872719
[TBL] [Abstract][Full Text] [Related]
7. Mutation of tumor suppressor gene p53 is frequently found in vulvar carcinoma cells.
Hietanen SH; Kurvinen K; Syrjänen K; Grénman S; Carey T; McClatchey K; Syrjänen S
Am J Obstet Gynecol; 1995 Nov; 173(5):1477-82. PubMed ID: 7503188
[TBL] [Abstract][Full Text] [Related]
8. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.
Cornelis RS; van Vliet M; Vos CB; Cleton-Jansen AM; van de Vijver MJ; Peterse JL; Khan PM; Børresen AL; Cornelisse CJ; Devilee P
Cancer Res; 1994 Aug; 54(15):4200-6. PubMed ID: 8033152
[TBL] [Abstract][Full Text] [Related]
9. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines.
Hsu IC; Tokiwa T; Bennett W; Metcalf RA; Welsh JA; Sun T; Harris CC
Carcinogenesis; 1993 May; 14(5):987-92. PubMed ID: 8389256
[TBL] [Abstract][Full Text] [Related]
10. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model.
Ko SC; Gotoh A; Thalmann GN; Zhau HE; Johnston DA; Zhang WW; Kao C; Chung LW
Hum Gene Ther; 1996 Sep; 7(14):1683-91. PubMed ID: 8886839
[TBL] [Abstract][Full Text] [Related]
11. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas.
Wagata T; Shibagaki I; Imamura M; Shimada Y; Toguchida J; Yandell DW; Ikenaga M; Tobe T; Ishizaki K
Cancer Res; 1993 Feb; 53(4):846-50. PubMed ID: 8094033
[TBL] [Abstract][Full Text] [Related]
12. Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation.
Colletier PJ; Ashoori F; Cowen D; Meyn RE; Tofilon P; Meistrich ME; Pollack A
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1507-12. PubMed ID: 11121656
[TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity and overexpression of p53 gene in human primary prostatic adenocarcinoma.
Fan K; Dao DD; Schutz M; Fink LM
Diagn Mol Pathol; 1994 Dec; 3(4):265-70. PubMed ID: 7866637
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic and genotypic characterization of commonly used human prostatic cell lines.
Mitchell S; Abel P; Ware M; Stamp G; Lalani E
BJU Int; 2000 May; 85(7):932-44. PubMed ID: 10792179
[TBL] [Abstract][Full Text] [Related]
15. p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency.
Frankel RH; Bayona W; Koslow M; Newcomb EW
Cancer Res; 1992 Mar; 52(6):1427-33. PubMed ID: 1347252
[TBL] [Abstract][Full Text] [Related]
16. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma.
von Deimling A; Eibl RH; Ohgaki H; Louis DN; von Ammon K; Petersen I; Kleihues P; Chung RY; Wiestler OD; Seizinger BR
Cancer Res; 1992 May; 52(10):2987-90. PubMed ID: 1349850
[TBL] [Abstract][Full Text] [Related]
17. p53 protein accumulation and gene mutations in human glioma cell lines.
Anker L; Ohgaki H; Ludeke BI; Herrmann HD; Kleihues P; Westphal M
Int J Cancer; 1993 Dec; 55(6):982-7. PubMed ID: 8253536
[TBL] [Abstract][Full Text] [Related]
18. Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines.
Kim JH; Takahashi T; Chiba I; Park JG; Birrer MJ; Roh JK; De Lee H; Kim JP; Minna JD; Gazdar AF
J Natl Cancer Inst; 1991 Jul; 83(13):938-43. PubMed ID: 1676761
[TBL] [Abstract][Full Text] [Related]
19. Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells.
Tepper CG; Gregg JP; Shi XB; Vinall RL; Baron CA; Ryan PE; Desprez PY; Kung HJ; deVere White RW
Prostate; 2005 Dec; 65(4):375-89. PubMed ID: 16037992
[TBL] [Abstract][Full Text] [Related]
20. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression.
Fults D; Brockmeyer D; Tullous MW; Pedone CA; Cawthon RM
Cancer Res; 1992 Feb; 52(3):674-9. PubMed ID: 1346255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
